Pharmacotherapy of Child and Adolescent Psychiatric Disorders

Informationen zum Autor David Rosenberg MD , Miriam L. Hamburger Endowed Chair of Child Psychiatry and Professor & Chief of Child Psychiatry and Psychology at Wayne State University and the Children's Hospital of Michigan, Detroit, MI , USA Samuel Gershon MD , Emeritus Professor of Psychiatry, University of Pittsburgh, PA, USA Klappentext This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.* Third edition of the first ever book published on pediatric psychopharmacology from renowned editors.* Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.* Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.* Features many tables, figures and pictorials, making it highly accessible and reader friendly. Zusammenfassung Focusing on pediatric psychopharmacology, this title covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, such as schizophrenia or bipolar disorder, but who are deemed to be at high risk. It addresses concerns about cardiovascular side effects of the stimulant medications available. Inhaltsverzeichnis List of Contributors, xv Foreword, xix Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology, 1 Samuel Gershon References, 4 Chapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth, 7 Daniel J. Safer & Julie Magno Zito Introduction, 7 Prevalence and trends for medications prescribed for ADHD, 8 Nonstimulant medications for ADHD, 11 Antidepressant medication, 11 Antipsychotic medication, 13 Alpha-agonists, 14 Anticonvulsant "mood stabilizers", 15 Concomitant psychotropic medication, 15 Preschool psychotropic medication use, 17 International patterns of psychotropic medication for youth, 17 Conclusion, 18 References, 18 Chapter 3 Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry, 25 C. Lindsay DeVane Introduction, 25 Extent of off-label prescribing, 27 Need for psychoactive drug treatments for children and adolescents, 31 Legislation supporting pediatric drug development, 33 Recommendations to follow when considering off-label prescribing, 35 References, 36 Chapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology, 39

List of contents

List of Contributors, xv
 
Foreword, xix
 
Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology, 1
Samuel Gershon
 
References, 4
 
Chapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth, 7
Daniel J. Safer & Julie Magno Zito
 
Introduction, 7
 
Prevalence and trends for medications prescribed for ADHD, 8
 
Nonstimulant medications for ADHD, 11
 
Antidepressant medication, 11
 
Antipsychotic medication, 13
 
Alpha-agonists, 14
 
Anticonvulsant "mood stabilizers", 15
 
Concomitant psychotropic medication, 15
 
Preschool psychotropic medication use, 17
 
International patterns of psychotropic medication for youth, 17
 
Conclusion, 18
 
References, 18
 
Chapter 3 Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry, 25
C. Lindsay DeVane
 
Introduction, 25
 
Extent of off-label prescribing, 27
 
Need for psychoactive drug treatments for children and adolescents, 31
 
Legislation supporting pediatric drug development, 33
 
Recommendations to follow when considering off-label prescribing, 35
 
References, 36
 
Chapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology, 39
Richard I. Shader & Christopher-Paul Milne
 
What is a generic drug?, 39
 
Why are we discussing generic drugs?, 39
 
Basic requirements for generic drugs, 40
 
The status of regulations regarding generic drugs and children, 41
 
Abbreviated new drug application (ANDA) requirements, 42
 
Pediatric assessments of adult drugs (history up to current status), 43
 
Best Pharmaceuticals for Children Act, 44
 
Pediatric Research Equity Act, 45
 
Intersection of requirements for generics and pediatric assessment, 46
 
Future directions, 48
 
Concluding thoughts, 49
 
References, 49
 
Chapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology, 51
David J. Edwards
 
Introduction, 51
 
Basic concepts in pharmacokinetics, 52
 
Dosing considerations for psychoactive drugs in children, 55
 
Summary, 60
 
References, 60
 
Chapter 6 Psychostimulants, 65
Steven R. Pliszka
 
Introduction, 65
 
Epidemiology of stimulant use, 66
 
Structure and biochemical mechanism of action, 66
 
Neuroimaging studies of stimulant effects, 67
 
Studies of short-term efficacy, 72
 
Studies of long-term efficacy, 76
 
Clinical use, 79
 
Common side-effects, 84
 
Cardiovascular safety issues, 86
 
Growth suppression, 88
 
Substance use and diversion, 88
 
Comparison with nonstimulant treatment, 89
 
Treatment of comorbidity, 92
 
Pharmacogenetics, 93
 
Conclusions, 94
 
References, 94
 
Chapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders, 105
Charlotte M. Heleniak, Tejal Kaur, Kareem D. Ghalib & Moira A. Rynn
 
Tricyclic antidepressants (TCAs), 105
 
Drug interactions, contraindications, 116
 
Monoamine oxidase inhibitors (MAOIs), 117
 
General summary, 122
 
References, 123
 
Chapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs), 131
Dara Sakolsky & Boris Birmaher
 
Pharmacokinetics, 131
 
Initiation and titration, 133
 
Indications and efficacy, 134
 
Adverse effects, 146
 
Withdrawal, 149
 
References, 149
 
Chapter 9 Novel

Report

"Pharmacotherapy of Child and Adolescent PsychiatricDisorders is a book to have available on your desk, not just inyour library. It provides ready access to the wealth ofpractical information and insight for the range of health andmental health professionals. It is highly recommended fortrainees and anyone who is prescribing psychotropic medications tothe pediatric population and young adults." ( Journalof Clinical Psychiatry , 7 July 2012)

Product details

• Authors: Samuel Gershon, D Rosenberg, David Rosenberg, David (Wayne State University) Gershon Rosenberg, David Gershon Rosenberg, David R. Gershon Rosenberg
• Assisted by: Gershon (Editor), Gershon (Editor), Samuel Gershon (Editor), Gershon Samuel (Editor), Davi Rosenberg (Editor), David Rosenberg (Editor), David R. Rosenberg (Editor)
• Publisher: Wiley, John and Sons Ltd
• Languages: English
• Product format: Hardback
• Released: 03.02.2012
• EAN: 9780470973769
• ISBN: 978-0-470-97376-9
• No. of pages: 474
• Subjects: Natural sciences, medicine, IT, technology > Medicine > Non-clinical medicine; Medizin, Psychopharmakologie, MEDICAL / Pediatrics, MEDICAL / Psychiatry / Psychopharmacology, Psychopharmacology, Medical Science, Paediatric medicine / child and adolescent medicine